GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: JNJ-78278343 | JNJ78278343
Compound class:
Antibody
Comment: Pasritamig (JNJ-78278343) is a bispecific kallikrein related peptidase 2 (KLK2)/CD3e monoclonal antibody. It acts as a T-cell engager targeting KLK2 on tumour cells.
The peptide sequences for the heavy and light chains of pasritamig's KLK2 binding domain are claimed in patent US11965024B2 [1] and are a component of the antibody named KL2B30. The anti-cD3e component is claimed in patent US11827708B2 [2]. |
| Bioactivity Comments |
| The KLK2/CD3e bispecific antibodies in patent US11965024B2 were evaluated for cytotoxicity in KLK2-expressing target cells [1]. Quantitative binding affinities for the antigens don't appear to have been determined. |
| Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
